US-based medical and diagnostic laboratory Satio and digital diagnostics provider Nanowear have announced a collaboration to advance home-based diagnostic and therapeutic care.
The partnership will integrate Nanowear’s AI-based nanotechnology biomarker diagnostic platform with Satio’s blood draw diagnostics and drug delivery systems.
The integration aims to combine in-vivo and in-vitro diagnostics for precision therapeutics and AI-based risk assessment.
Nanowear is revolutionising home-based cardiometabolic healthcare with its FDA-approved cloth nanotechnology and AI diagnostics platform, SimpleSense.
The platform offers a comprehensive cardiometabolic assessment by collecting over 85 clinically validated biomarkers.
It replaces traditional diagnostic tools such as ECGs, digital stethoscopes, and glucose monitors, all while patients remain at home.
Nanowear CEO and co-founder Venk Varadan said: “This collaboration of the technologies that combine these key determinants of human health results in a first-of-its-kind platform that will truly unlock early diagnosis and precision medicine.”
“Precision medicine, individualized risk assessment, early diagnosis, home-based care… these were big buzzwords that helped frame the digital health landscape post-2020 pandemic.
“What’s been holding these capabilities back is the inability to time-synchronously combine all of the relevant biomarkers that are individual to our unique bodies.
“When all of the health determinant biomarkers are available through a single data fire hose, AI precision medicine will make us healthier and save our healthcare system trillions.”
Satio’s remotely controlled drug delivery telemedicine episode has been identified as the first Advanced Research Development Agency for Health (ARPA-H) Challenge programme.
The company’s patch-based adhesive technology facilitates decentralised care by shifting blood-based diagnostics and drug delivery from clinics to homes.
The partnership will explore ways to advance home-based diagnostics and care by integrating Satio’s SatioDot and SatioDraw patches with Nanowear’s SimpleSense system.
The combination of blood and genotype biomarkers with cardiometabolic data represents a significant advancement in clinical research, a market worth around $55bn each year.
In addition, Nanowear’s SimpleSense biomarkers will be integrated into SatioRx’s telehealth drug delivery system, enhancing home-based care in a market valued at around $200bn.
Both companies will jointly promote their technologies to key stakeholders, accelerating innovation in digital healthcare.
Satio founder and chairman Namal Nawana said: “We are excited about the opportunities to merge in vitro and in vivo results and to enhance chronic disease, cardiometabolic and cancer drug delivery.
“And as I’ve seen in diagnostics and orthopedics, shifting care away from brick and mortar requires not just disrupting workflow, but ensuring information flow is enhanced.
“This partnership will help ensure the patient’s ease of mind and the clinician’s decision-making are strengthened, not thrown into doubt.”
